{"id":1252,"date":"2025-05-08T14:53:00","date_gmt":"2025-05-08T14:53:00","guid":{"rendered":"https:\/\/retina-eye.co.uk\/?p=1252"},"modified":"2026-09-01T03:24:49","modified_gmt":"2026-09-01T03:24:49","slug":"real-world-data-on-outcomes-of-diabetic-macular-oedema-patients-treated-with-vabysmo-vs-eylea-intravitreal-antivegf-injections","status":"publish","type":"post","link":"https:\/\/www.retina-eye.co.uk\/zh\/post\/real-world-data-on-outcomes-of-diabetic-macular-oedema-patients-treated-with-vabysmo-vs-eylea-intravitreal-antivegf-injections\/","title":{"rendered":"\u771f\u5b9e\u7684\u4e16\u754c\u4e0a\u7684\u6570\u636e\u7ed3\u679c\u7684\u7cd6\u5c3f\u75c5\u89c6\u7f51\u819c\u9ec4\u6591\u6c34\u80bf\u75c5\u4eba\u6cbb\u7597\u4e0eVabysmo vs Eylea\u73bb\u7483\u4f53\u5185Antivegf\u6ce8\u5c04"},"content":{"rendered":"

Fresh on presentation at international conference: ARVO-Salt Lake City, Utah 2025<\/em><\/p>\r\n\r\n\r\n\r\n

Ms\u6052\u548c\u56e2\u961f\u5df2\u7ecf\u6709\u4e86\u65b0\u7684\u533b\u7597\u6570\u636e\u63d0\u51fa\u4e86\u5728ARVO\u4f1a\u8bae\u57282025\u5e74\u3002<\/em><\/p>\r\n\r\n\r\n\r\n

\u4e00\u4e2a\u6f14\u793a\u770b\u7684\uff1a<\/p>\r\n\r\n\r\n\r\n

Preliminary\u00a0Results of a Real-World Comparative Analysis of Anatomical and Visual Outcomes in Diabetic Macular Oedema\u00a0(DMO)\u00a0Patients\u00a0Treated with\u00a0Faricimab\u00a0or\u00a0Aflibercept Injections\u00a0<\/h2>\r\n\r\n\r\n\r\n

This study aims to\u00a0compare\u00a0real-world anatomical and visual outcomes\u00a0of DMO patients commenced on\u00a0\u6cd5\u745e\u897f\u5355\u6297<\/u><\/a>\u00a0\u6216 \u963f\u67cf\u897f\u666e<\/u><\/a> injection at a\u00a0tertiary care center in the\u00a0United Kingdom\u00a0(UK).<\/p>\r\n\r\n\r\n\r\n

\u00a0<\/p>\r\n\r\n\r\n\r\n

Retrospective analysis of all DMO patients\u00a0who had not received any intravitreal treatment for at least 6 months and commenced on\u00a0Faricimab\u00a0or Aflibercept at\u00a0Moorfields\u00a0Ealing\u00a0outreach\u00a0(UK)\u00a0between\u00a01 October 2022\u00a0to\u00a01 April 2024.\u00a0<\/p>\r\n\r\n\r\n\r\n

\u60a3\u8005\u7684\u4eba\u53e3\u7edf\u8ba1\uff0c \u7cd6\u5c3f\u75c5\u89c6\u7f51\u819c\u75c5\u53d8<\/u><\/a> stage,\u00a0attendance rate,\u00a0visual acuity\u00a0(VA),central subfield\u00a0thickness(CST)\u00a0and\u00a0macular fluid status at baseline and after each injection were assessed.\u00a0<\/p>\r\n\r\n\r\n\r\n

Treatment intervals and adverse events were also recorded.\u00a0Statistical analysis was performed using SPSS 21.0.0 software.<\/p>\r\n\r\n\r\n\r\n

\u00a0<\/p>\r\n\r\n\r\n\r\n

A total of\u00a0146 DMO eyes were included\u00a0in the study,divided into two subgroups: 83 eyes initiated on aflibercept and 63 on\u00a0Faricimab.\u00a0Mean age was 63.3\u00b111.2years with females being 51.4%.\u00a025.3% were Caucasian and 32.9% were\u00a0Indians.\u00a0<\/p>\r\n\r\n\r\n\r\n

Baseline mean VA and CST\u00a0were 62.9\u00b115.3ETDRS letters and 387.0\u00b190.1\u03bcm\u00a0for the aflibercept subgroup,\u00a0and\u00a059.4\u00b117.5ETDRS letters\u00a0and 427.5\u00b1114.6\u03bcm\u00a0for the\u00a0Faricimab\u00a0subgroup.\u00a0<\/p>\r\n\r\n\r\n\r\n

VA improvements\u00a0compared to baseline\u00a0after each of the first 3 injections were\u00a0+3.3, +2.1\u00a0and\u00a0+3.0 ETDRS letters\u00a0for aflibercept\u00a0and\u00a0+1.9, +5.0\u00a0and\u00a0+5.2 ETDRS letters\u00a0for\u00a0Faricimab\u00a0(p=0.6).\u00a0CST\u00a0reductions\u00a0compared\u00a0to\u00a0baseline after each of the first 3 injections\u00a0were -78.7, -91.1\u00a0and\u00a0-91.7\u03bcm\u00a0for Aflibercept\u00a0and\u00a0-82.2, -118.0, -137.5\u03bcm\u00a0for\u00a0Faricimab (p=0.02 after 3 injections).\u00a0<\/p>\r\n\r\n\r\n\r\n

The proportion of dry\u00a0macula after each injection were\u00a02.5%, 4.2%, 6.6% for the Aflibercept subgroup and 3.2%, 6.8% and 7.4% for the\u00a0Faricimab\u00a0subgroup respectively (p=0.6).\u00a0Non attendance\u00a0rates\u00a0for\u00a0the 2nd, 3rd\u00a0and 4th\u00a0injection were 3.6%, 15.6%, 27.7%\u00a0for\u00a0Aflibercept\u00a0and 3.1%, 7.9% and 14.2%\u00a0for\u00a0Faricimab. No cases\u00a0of anterior uveitis or endophthalmitis were\u00a0observed.<\/p>\r\n\r\n\r\n\r\n

\u00a0<\/p>\r\n\r\n\r\n\r\n

This study showed that both\u00a0Faricimab\u00a0and Aflibercept loading\u00a0injections\u00a0result in visual and anatomical improvement for DMO in real-world settings, although the proportion of dry macula remains low after three injections\u00a0suggesting the need for longer loading phase.\u00a0Faricimab\u00a0tended towards\u00a0more rapid improvement\u00a0but\u00a0ceiling effect in the aflibercept group\u00a0cannot be excluded. Further studies are needed to\u00a0compare these treatments in real-world practice.<\/p>\r\n\r\n\r\n\r\n

\"\"<\/figure>\r\n\r\n\r\n\r\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Fresh on presentation at international conference: ARVO-Salt Lake City, Utah 2025 Ms Heng and team have had new medical data presented at the ARVO conference in 2025. One of the presentations looked at: Preliminary\u00a0Results of a Real-World Comparative Analysis of Anatomical and Visual Outcomes in Diabetic Macular Oedema\u00a0(DMO)\u00a0Patients\u00a0Treated with\u00a0Faricimab\u00a0or\u00a0Aflibercept Injections\u00a0 This study aims to\u00a0compare\u00a0real-world anatomical […]<\/p>\n","protected":false},"author":1,"featured_media":1253,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[232,215,72,235,231,234,230,233],"class_list":["post-1252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-aflibercept-injections","tag-diabetic-macular-oedema-dmo","tag-diabetic-retinopathy","tag-dry-macula","tag-faricimab","tag-intravitreal-treatment","tag-real-world-data","tag-visual-outcomes-of-dmo-patients"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t